A study from the Keck School of Medicine of USC finds that a peptide only found in Old World monkeys has the potential to stop rheumatoid arthritis progression better than established treatments
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was a particular peptide only found in Old World monkeys, called ?-defensin 1 (RTD-1), that the researchers believed had the potential to stop — or even reverse — the progression of rheumatoid arthritis, an autoimmune disease that affects about 1.5 million people in the United States. The promising results of their study were published today in PLOS ONE.
“RTD-1 is the prototype of a family of small cyclic peptides (?-defensins), the only circular proteins in the animal kingdom,” says study author Michael Selsted, MD, PhD, chair and professor of pathology at the Keck School. “Previous studies have shown that RTD-1 modulates lethal inflammation in animal models of infection, and we predicted that RTD-1’s protective mechanism in those models would translate to rheumatoid arthritis, a disease in which chronic inflammation produces irreversible joint damage.”
To test their hypothesis, the researchers administered RTD-1 to rats with arthritis for 11 days and observed whether the treatment had any anti-arthritic effects. Within 24 hours of the first administered dose, RTD-1 had significantly reduced arthritis progression. At the end of the treatment, rats that received RTD-1 also had markedly lower arthritis severity scores as compared with rats that had not received RTD-1.
Next, RTD-1 was tested in rats with severe arthritis. The research team found that RTD-1 produced a rapid reduction in arthritis severity within 48 hours of treatment, with complete resolution of clinical disease in all treated rats by day 15.
RTD-1 was then compared to two gold standard treatments for rheumatoid arthritis — methotrexate and etanercept — in rats with severe arthritis. The team found that RTD-1 treatment resulted in greater disease resolution than methotrexate or etanercept. RTD-1 also achieved the highest rate of complete disease resolution of the three treatments.
“Since most available rheumatoid arthritis therapies achieve mild to moderate improvements, and disease remission is rare, there’s a continuing search for new therapeutics,” Selsted says. “Our findings strongly suggest that RTD-1 has potential as a completely new agent for treating rheumatoid arthritis. RTD-1-like molecules may also be effective in the treatment of other inflammatory diseases and cancer.”
The Latest on: RTD-1
- Boyz II Men Performed a Touching Song for Your Mom on 'SNL'on May 10, 2020 at 8:30 am
Someone, please make sure Betty White is still staying safely inside her home!! This year, we got a special performance from Boyz II Men, who together with their impressive facial hair, performed a ...
- Remote Three-Wire RTDs Can Multiplex Accurately To Measurement Systemon May 7, 2020 at 5:00 pm
Each remote RTD to be measured has four single-pole, single-throw (SPST) CMOS switches associated with it: SW1a through SW1d for RTD#1, all the way up to SW8a through SW8d for RTD#8. The four ...
- WATCH NOW: Northam says Virginia localities can set stricter restrictions once state begins phased reopeningon May 7, 2020 at 8:01 am
Gov. Ralph Northam said Wednesday that the guidelines for a phased reopening of the state will serve as a “floor” for localities — meaning they can impose stricter restrictions — after ...
- Journal of medicinal chemistryon April 28, 2020 at 5:00 pm
Accepting the Invitation to Open Innovation in Malaria Drug Discovery: Synthesis, Biological Evaluation, and Investigation on the Structure-Activity Relationships of Benzo[b]thiophene-2 ...
via Google News and Bing News